Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1997 1
2000 1
2006 1
2007 1
2008 1
2009 1
2010 1
2012 1
2016 1
2020 3
2021 5
2022 6
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions.
Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, Schmid M, Silva R, Cunha-Vaz J, Tufail A, Weissgerber G, Leal S, Holz FG, Finger RP; on behalf of the MACUSTAR Consortium. Terheyden JH, et al. Among authors: weissgerber g. Ophthalmologica. 2021;244(5):387-395. doi: 10.1159/000513591. Epub 2020 Dec 7. Ophthalmologica. 2021. PMID: 33285549 Free article. Review.
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D'Souza D, Weissgerber G, Gedif K, Koh A. Ogura Y, et al. Among authors: weissgerber g. Br J Ophthalmol. 2022 Jul;106(7):994-999. doi: 10.1136/bjophthalmol-2021-319090. Epub 2021 Jul 22. Br J Ophthalmol. 2022. PMID: 34301613 Free PMC article. Clinical Trial.
Challenges, facilitators and barriers to screening study participants in early disease stages-experience from the MACUSTAR study.
Terheyden JH, Behning C, Lüning A, Wintergerst L, Basile PG, Tavares D, Melício BA, Leal S, Weissgerber G, Luhmann UFO, Crabb DP, Tufail A, Hoyng C, Berger M, Schmid M, Silva R, Martinho CV, Cunha-Vaz J, Holz FG, Finger RP; MACUSTAR consortium. Terheyden JH, et al. Among authors: weissgerber g. BMC Med Res Methodol. 2021 Mar 17;21(1):54. doi: 10.1186/s12874-021-01243-8. BMC Med Res Methodol. 2021. PMID: 33731014 Free PMC article.
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration.
Poor SH, Weissgerber G, Adams CM, Bhatt H, Browning DJ, Chastain J, Ciulla TA, Ferriere M, Gedif K, Glazer LC, Joondeph BC, Normand G, Sheth V, Watters C, Grosskreutz CL. Poor SH, et al. Among authors: weissgerber g. Am J Ophthalmol. 2022 Jul;239:180-189. doi: 10.1016/j.ajo.2022.02.019. Epub 2022 Mar 2. Am J Ophthalmol. 2022. PMID: 35247334 Free article. Clinical Trial.
20 results